[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Assaf-Harofeh Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":609},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,40,65,99,123,151,174,195,215,235,257,279,303,322,353,377,397,420,443,467,496,522,545,567,587],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100642708","dietary-modulation-of-urinary-mcp-1-in-adpkd-100642708",false,"NCT07651397","Dietary Modulation of Urinary MCP-1 in ADPKD","Open Labeled , Randomized, Controlled, Crossover Trial on the Effect of a Carbohydrate Restricted Plant Dominant Diet on MCP-1 Mediated Inflammatory Signaling in Autosomal Dominant Polycystic Kidney Disease","Inclusion Criteria:\n\n1. Age ≥18\n2. Diagnosis of ADPKD based on established clinical or genetic criteria (PKD 1\u002FPKD2)\n3. Estimated glomerular filtration rate (eGFR) between 45 and 90 mL\u002Fmin\u002F1.73 m²\n4. Mayo Imaging Classification class 1C-1E based on MRI-derived height-adjusted total kidney volume.\n5. Stable kidney function, defined as no acute kidney injury and no decline in eGFR \\>20% within the preceding 3 months\n6. Stable antihypertensive and chronic medications for at least 4 weeks prior to enrollment\n7. Ability and willingness to adhere to the prescribed dietary intervention\n8. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m² or requirement for dialysis\n2. History of kidney transplantation\n3. Significant albuminuria, defined as urine albumin to creatinine ratio (UACR) \\>300 mg\u002Fg\n4. Poorly controlled or unstable diabetes mellitus (e.g., HbA1c \\>8% or clinically significant glycemic variability or frequent hypoglycemia)\n5. Use of Tolvaptan at the time of screening or within the study period\n6. Current adherence to a ketogenic or carbohydrate restricted diet\n7. Unintentional weight loss \\>5% within the preceding 3 months\n8. Active infection, inflammatory disease, or malignancy that may influence inflammatory markers\n9. Current use of systemic corticosteroids or immunosuppressive therapy\n10. Active or symptomatic nephrolithiasis\n11. Serum bicarbonate \\\u003C20 mmol\u002FL\n12. Pregnancy or breastfeeding\n13. Known eating disorder or condition limiting adherence to dietary interventions\n14. Participation in another interventional study within the previous 3 months\n15. Any condition that, in the opinion of the investigators, would interfere with study participation or interpretation of results","ALL","18 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"NA","Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth and declining kidney function. Inflammatory pathways, including those mediated by monocyte chemoattractant protein-1 (MCP-1), are increasingly recognized as contributors to disease progression. Metabolic alterations in cystic epithelial cells may influence inflammatory signaling, suggesting a potential role for dietary interventions targeting metabolic pathways.\n\nThis study is a prospective, randomized, open-label crossover trial designed to evaluate the effect of a carbohydrate restricted, plant dominant dietary intervention on urinary MCP-1 levels in adults with ADPKD. Participants will be randomized to one of two sequences: dietary intervention followed by usual diet, or usual diet followed by dietary intervention, with a washout period between study phases. Each study period will last 12 weeks.\n\nThe primary objective is to assess within subject differences in urinary MCP-1\u002Fcreatinine ratio between the dietary intervention and usual diet conditions. Secondary outcomes include measures of metabolic parameters, insulin resistance, dietary adherence, and safety.\n\nThis study aims to explore whether a structured dietary approach may influence intrarenal inflammatory activity in ADPKD and provide preliminary data to inform future interventional studies.",[27],"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","NOT_YET_RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":21},"2026-07-10",{"date":36,"type":21},"2029-01-01",{"name":38,"class":39},"Assaf-Harofeh Medical Center","OTHER_GOV",{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100639749","hyperbaric-oxygen-therapy-for-chronic-fatigue-syndrome-cfs-100639749","NCT07621068","Hyperbaric Oxygen Therapy for Chronic Fatigue Syndrome (CFS)","Hyperbaric Oxygen Therapy for Chronic Fatigue Syndrome (CFS) - A Prospective, Randomized, Double-Blind, Sham-Controlled Study","Inclusion Criteria:\n\n* Subject willing and able to read, understand and sign an informed consent\n* Diagnosis of mild to moderate severity of Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome\n* Patients diagnosed with CFS for more than 1 years\n* Stable psychological and pharmacological treatment for more than three months prior to inclusion\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits and\u002For comply with the study protocol\n2. Severe and very severe cases of ME\u002FCFS\n3. History or diagnosis of, brain tumors, brain surgery, epilepsy, neurodegenerative diseases\n4. Active malignancy\n5. Substance use at baseline, except for prescribed cannabis if vaporized or taken PO as tincture\n6. Active smokers\n7. Chronic heart failure with ejection fraction of 30 or less\n8. Chest pathology incompatible with pressure changes (including active asthma or COPD)\n9. Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologist visits a year)\n10. Pregnancy\n11. An inability to perform an awake brain MRI\n12. An inability to perform Neurotrax\n13. Participation in another medical study\n14. HBOT for any reason prior to study enrolment",{"count":48,"type":21},74,[24],"This study evaluates the effects of hyperbaric oxygen therapy (HBOT) in patients with mild to moderate CFS\u002FME. Participants will undergo 60 HBOT sessions over 3 months with a 3-month follow-up, including physical, cognitive, imaging, and laboratory assessments.",[52],"Chronic Fatigue Syndrome",[54,55],"Hyperbaric oxygen therapy","Myalgic Encephalomyelitis","2026-05-27",{"date":58,"type":32},"2026-06-02",{"date":60,"type":21},"2026-06",{"date":62,"type":21},"2027-06",{"name":38,"class":39},1,{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100638741","retrospective-analysis-of-cpet-and-cognitive-tests-of-healthy-individuals-treated-with-60-treatment-of-hbot-100638741","NCT07596641","Retrospective Analysis of CPET and Cognitive Tests of Healthy Individuals, Treated With 60 Treatment of HBOT","Retrospective Analysis of Cardiopulmonary Exercise Tests and Cognitive Tests of Healthy Individuals Age 18+ Years, Treated at the Sagol Center for Hyperbaric Medicine and Research With 60 Hyperbaric Oxygen Therapy Treatments.","HBOT","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* Completed a full treatment series of 60 hyperbaric oxygen therapy (HBOT) sessions at the Sagol Center\n* Availability of pre- and post-treatment cardiopulmonary exercise testing (CPET) data\n* Availability of pre- and post-treatment cognitive assessment data\n\nExclusion Criteria:\n\n* Inability to complete a maximal CPET test, pre and post HBOT or Missing pre- or post-treatment CPET data.\n* Incomplete HBOT treatment series\n* Missing cognitive assessment data",true,"65 Years",{"count":76,"type":21},1000,"OBSERVATIONAL","This retrospective observational study evaluates physiological and cognitive changes following a series of 60 hyperbaric oxygen therapy (HBOT) sessions in healthy individuals. Participants underwent treatment five days per week, each session included 90 minutes exposure to 100% oxygen at 2ATA with a five-minute air break every 20 minutes. Pre- and post-treatment data include cardiopulmonary exercise testing (CPET) and standardized cognitive assessments. The study aims to characterize associations between changes in cardiorespiratory fitness and cognitive performance following repeated HBOT exposure in a real-world clinical cohort",[80,81,82],"Hyperbaric Oxygenation","Cardiorespiratory Fitness","Cognition",[71,84,85,86,87,88,89,90],"VO2MAX","VO2 PEAK","cognitive function","CPET","cardiopulmonary exercise testing","hyperbaric oxygen therapy","HEALTH","2026-05-17",{"date":93,"type":32},"2026-05-19",{"date":95,"type":21},"2026-12-01",{"date":97,"type":21},"2028-03-30",{"name":38,"class":39},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":73,"sex":105,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":64},"100637365","comparison-of-3-tesla-mri-to-7-tesla-mri-for-evaluation-of-prostate-suspicion-lesions-100637365","NCT07603908","Comparison of 3 Tesla MRI to 7 Tesla MRI for Evaluation of Prostate Suspicion Lesions","Inclusion Criteria:\n\n* male patients referred for clinical 3T prostate MRI at Shamir Medical Center\n* male patients who consent to undergo an additional 7T scan at the Weizmann Institute.\n\nExclusion Criteria:\n\n* Contraindications to MRI (e.g., non-compatible implants, pacemakers, severe claustrophobia)\n* diabetes mellitus\n* glucose intolerance\n* hyperglycemia\n* hyperlactatemia\n* chronic kidney disease (GFR \\\u003C45 mL\u002Fmin\u002F1.73 m2).","MALE","75 Years",{"count":108,"type":21},200,[24],"A comparison of 3 Tesla MRI to 7 Tesla MRI for Evaluation of Prostate Suspicious Lesions.\n\nAssess the added diagnostic value of ultra-high-field (7T) MRI over the current clinical standard (3T MRI) in detecting and characterizing suspicious prostate lesions. Evaluate whether dynamic deuterated glucose-enhanced imaging at 7T can offer improved contrast without the use of gadolinium-based agents.",[112],"Prostate Nodule",[114,115],"3T MRI","7T MRI",{"date":117,"type":32},"2026-05-22",{"date":119,"type":21},"2027-01",{"date":121,"type":21},"2030-01",{"name":38,"class":39},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":64},"100635918","effect-of-hyperoxygenated-environment-on-maximal-muscle-strength-100635918","NCT07558928","Effect of Hyperoxygenated Environment on Maximal Muscle Strength","Effect of Hyperoxygenated Environment on Maximal Muscle Strength in the Mid-thigh Pull Test - a Blinded, Randomized, Sham-Controlled Crossover Study","force","Inclusion Criteria:\n\n1. Healthy\n2. Ages 18-45\n3. Participants are physically active and have a recent resistance-training experience of at least six months, ≥ 3 times a week\n4. Participant willing and able to read, understand and sign an informed consent\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits or comply with the study protocol\n2. Active malignancy\n3. Active smokers\n4. Previous treatment of hyperbaric chamber for any reason prior to study enrollment.\n5. Chest pathology incompatible with pressure changes\n6. Major orthopedic injury at the past 3 months\n7. Inner ear disease\n8. Lung pathology\n9. Claustrophobia\n10. Previous neurologic conditions (e.g., epilepsy, brain tumors or s\u002Fp neurosurgery etc.)\n11. Comorbidities and medications that rule out the subject","45 Years",{"count":133,"type":21},48,[24],"comparing the effect of hyperoxygenated environment on maximal muscle strength in the Mid-thigh Pull Task",[137],"Healthy Lifestyle",[139,140,129,141],"power lifting","gym","imtp","RECRUITING","2026-04-26",{"date":145,"type":32},"2026-04-30",{"date":147,"type":32},"2024-01-01",{"date":149,"type":21},"2027-12-31",{"name":38,"class":39},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":64},"100634424","cross-modal-correlation-of-eeg-and-mri-functional-connectivity-an-investigative-study-100634424","NCT07539506","Cross Modal Correlation of EEG and MRI Functional Connectivity: An Investigative Study","Inclusion Criteria:\n\n* Male or females aged 18 years or older.\n* Performed a brain MRI at the Sagol Center MRI Unit, at the Shamir Medical Center\n* Able to cooperate in an EEG evaluation\n* Can read and sign the informed consent.\n\nExclusion Criteria:\n\n* Any scalp\u002Fbone abnormality incompatible with the EEG electrodes\n* Any known allergy to metals.\n* Inability to cooperate with simple instructions.\n* Inability to read and sign the informed consent.",{"count":158,"type":21},1500,[24],"Cross modal correlation of EEG and MRI functional connectivity: An Investigative Study. Correlating EEG Analysis with Brain Network Connectivity in Functional MRI. The primary aim of this study is to correlate correlation of MRI and EEG.",[162],"MRI, Functional MRI",[164,165],"Fmri","EEG","2026-04-20",{"date":168,"type":32},"2026-04-22",{"date":170,"type":32},"2024-04-02",{"date":172,"type":21},"2030-01-31",{"name":38,"class":39},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":64},"100554035","the-effect-of-hyperbaric-oxygen-therapy-for-acceleration-recovery-after-anterior-cruciate-ligament-reconstructionaclr-100554035","NCT06493851","The Effect of Hyperbaric Oxygen Therapy for Acceleration Recovery After Anterior Cruciate Ligament Reconstruction(ACLR)","The Effect of Hyperbaric Oxygen Therapy (HBOT) for Acceleration Recovery After Anterior Cruciate Ligament Reconstruction (ACLR): a Prospective, Randomized Control Study.","Inclusion Criteria:\n\n1. Subjects willing and able to read, understand and sign an informed consent\n2. Age 18-45\n3. Anterior cruciate ligament tear for reconstruction (with or without meniscal repair).\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits and\u002For comply with the study protocol\n2. Additional injury\n3. An inability to perform MRI.\n4. Active malignancy\n5. Chest pathology incompatible with pressure changes (including active asthma)\n6. Ear or sinus pathology incompatible with pressure changes\n7. History of epilepsy\n8. Claustrophobia\n9. Previous knee surgery\n10. Participation in another study",{"count":182,"type":21},40,[24],"The aim of the current study is to evaluate the effect of HBOT for acceleration recovery after ACLR.",[186],"Anterior Cruciate Ligament Reconstruction",[89],"2026-04-19",{"date":168,"type":32},{"date":191,"type":32},"2024-09-15",{"date":193,"type":21},"2028-01-01",{"name":38,"class":39},{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":73,"sex":105,"minAge":202,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":64},"100503974","hyperbaric-oxygen-therapy-for-men-suffering-from-infertility-due-to-oligospermia-100503974","NCT05842239","Hyperbaric Oxygen Therapy for Men Suffering From Infertility Due to Oligospermia.","Hyperbaric Oxygen Therapy for Men Suffering From Infertility Due to Oligospermia: a Pilot Study","Inclusion Criteria:\n\n1. Age above 21 years\n2. At least two sperm examination showing oligospermia (\\\u003C15·106 sperm\u002FmL)\n3. Diagnosis of idiopathic oligospermia.\n4. Subject willing and able to read, understand and sign an informed consent\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits and\u002For comply with the study protocol\n2. Active malignancy\n3. Previous treatment with chemotherapy and\u002For radiation therapy\n4. Substance use at baseline\n5. Severe or unstable physical disorders or major cognitive deficits at baseline\n6. HBOT for any reason prior to study enrolment\n7. Chest pathology incompatible with pressure changes (including moderate to severe asthma)\n8. Ear or Sinus pathology incompatible with pressure changes\n9. Chronic disease like diabetes mellitus, ischemic heart disease etc.\n10. Active smoking","21 Years",{"count":204,"type":21},15,[24],"Infertility in a couple is defined as the inability to achieve conception despite one year of frequent, unprotected intercourse. Infertility affects approximately 12% of couples attempting to conceive. The goal of this study is to explore the potential beneficial effect of HBOT on sperm count of infertile male due to oligospermia.",[208],"Oligospermia",{"date":168,"type":32},{"date":211,"type":32},"2024-01-20",{"date":213,"type":21},"2030-12-01",{"name":38,"class":39},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":234,"locationsCount":64},"100626016","long-lasting-effect-of-hyperbaric-oxygen-therapy-on-cognitive-function-in-traumatic-brain-injury-patients-100626016","NCT07430150","Long Lasting Effect of Hyperbaric Oxygen Therapy on Cognitive Function in Traumatic Brain Injury Patients","Inclusion Criteria:\n\n1. Diagnosed with traumatic brain injury\n2. Age 18 years or older at treatment\n3. Completed a 60 session hyperbaric treatment course at the Sagol Center for Hyperbaric Medicine and Research, Shamir Medical Center (Assaf Harofeh), and performed a neurocognitive evaluation by the computerized test Neurotrax.\n4. Willing and able to sign an informed consent. -\n\nExclusion Criteria:\n\n1. An inability to perform a neurocognitive computerized test.\n2. Any head trauma, neurodegenerative diseases or CVA after hyperbaric treatment completion.\n3. Diagnosis of a psychiatric disorder including: major depression, schizophrenia, bipolar disorder\n4. Active malignancy\n5. Chronic use of medications that may compromise cognitive function",{"count":222,"type":21},100,"To evaluate the cognitive functions of patients who suffered brain injury due to traumatic head injury and were previously treated in a hyperbaric chamber between one and four years after the end of treatment.",[225],"TBI (Traumatic Brain Injury)",[227],"Hyperbaric Therapy","2026-04-16",{"date":230,"type":32},"2026-04-21",{"date":232,"type":32},"2021-12-28",{"date":121,"type":21},{"name":38,"class":39},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":17,"minAge":242,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":64},"100625487","hyperbaric-oxygen-therapy-for-persistent-post-stroke-depression-100625487","NCT07423273","Hyperbaric Oxygen Therapy for Persistent Post Stroke Depression","Hyperbaric Oxygen Therapy for Persistent Post Stroke Depression: A Prospective, Randomized, Double Blind Study","Inclusion Criteria:\n\n1. Age between 50 -85\n2. Suffered an ischemic stroke 6 months to 7 years prior to their inclusion\n3. Treated or being treated by antidepressants for at least 3 months\n4. Diagnosis of PSD based on HDRS-17 score of 17 and above.\n5. Stable psychological and pharmacological treatment for more than three months prior to inclusion.\n6. Subject willing and able to read, understand and sign an informed consent.\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits and\u002For comply with the study protocol\n2. Diagnosis of a psychiatric disorder prior to the recent stroke including: major depression, schizophrenia or bipolar disease.\n3. Diagnosis of aphasia or major cognitive decline\n4. History of Deep brain stimulation (DBS)\n5. History of traumatic brain injury, brain tumors, brain surgery, chronic subdural haemorrhages, Epilepsy\n6. Active malignancy\n7. Substance use at baseline.\n8. History of other neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Lewy body dementia (LBD), Frontotemporal dementia (FTD), Multiple sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Creutzfeld Jacob disease (CJD), Multisystem atrophy (MSA), Pseudobulbar palsy (PSP), Corticobasal degeneration (CBD), Wernicke Korsakoff syndrome\n9. Serious suicidal ideation\n10. Renal or liver insufficiency, electrolyte imbalances\n11. Chronic heart failure with ejection fraction of 30 or less\n12. HBOT for any reason prior to study enrolment\n13. Chest pathology incompatible with pressure changes (including active asthma or COPD)\n14. Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologist visits a year)\n15. An inability to perform an awake brain MRI\n16. No evidence of vascular related lesions in the brain MRI\n17. Active smoking\n18. Participation in another study","50 Years","85 Years",{"count":245,"type":21},142,[24],"The study evaluates the effect of HBOT on depression in patients suffering from persistent symptoms of post stroke depression (PSD) in an double blind sham control study.",[249],"Post Stroke Depression",[89],{"date":252,"type":32},"2026-04-17",{"date":254,"type":32},"2023-11-08",{"date":213,"type":21},{"name":38,"class":39},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":73,"sex":17,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":64},"100573615","the-effect-of-hyperbaric-oxygen-therapy-on-circulating-hematopoietic-stem-cell-population-100573615","NCT06748586","The Effect of Hyperbaric Oxygen Therapy on Circulating Hematopoietic Stem Cell Population","The Effect of Hyperbaric Oxygen Therapy (HBOT) on Circulating Hematopoietic Stem Cell Population , A Prospective Study","Inclusion Criteria:\n\n* The study will include patients aged 20-80 who are intendent to start HBOT for other indication that are willing to give blood samples for measurements of circulating stem cells.\n\nExclusion Criteria:\n\n1. Active or recent infection within the last month\n2. Active malignancy.\n3. History of hematopoietic disease\n4. Low B12 or iron levels\n5. Inability to sign the informed consent form\n6. Leucocytes ˂4000 or ˃10,000","20 Years","80 Years",{"count":267,"type":21},60,[24],"Hematopoietic stem cells (HSCs), which govern the production of all blood lineages, transition through a series of functional states characterized by expansion during fetal development, functional quiescence in adulthood, and decline upon aging.\n\nAlthough research on aging has for a long time been relatively descriptive, much progress has been made in the past decade to uncover the molecular drivers of biological aging. One such drivers relates to stem cell exhaustion.\n\nThe amount and the function of HSCs decline in humans along aging. This decline is characterized by different changes such as signaling, epigenetic, cell surface markers etc. Various studies have been conducted to identify HSCs surface markers using flow cytometry.\n\nExposure to Hyperbaric Oxygen Therapy (HBOT) induce stem cells proliferation mobilization of stem progenitor cells (SPCs) in both animal and humans studies, and the number of SPCs remain elevated in blood over the course of 20 HBOT .\n\nAdditionally, Heyboer et al have found dose response curve between the HBOT protocol and circulating CD34+ and CD45-dim (stem cells potential markers): increasing the treatment pressure from 2.0 ATA to 2.5 ATA increased the concentration of circulating stem cells.\n\nThe aim of the current study is to evaluate the effect of HBOT on circulating hematopoietic stem cells, in the peripheral blood of patients who are candidate for HBOT.",[271],"Circulating Hematopoietic Stem Cells",[89],{"date":230,"type":32},{"date":275,"type":32},"2025-03-05",{"date":277,"type":21},"2027-12-30",{"name":38,"class":39},{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":73,"sex":105,"minAge":18,"maxAge":131,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":288,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":302,"locationsCount":64},"100473632","intermittent-hypoxic-training-iht-versus-hyperbaric-oxygen-therapy-hbot-for-aerobic-performance-100473632","NCT05447416","Intermittent Hypoxic Training (IHT) Versus Hyperbaric Oxygen Therapy (HBOT) for Aerobic Performance","Intermittent Hypoxic Training (IHT) Versus Hyperbaric Oxygen Therapy (HBOT) for Aerobic Performance - Prospective Randomized Study","Inclusion Criteria:\n\n1. Vo2max above 3500 ml or Vo2max\u002Fkg above 50 ml\u002Fkg\n2. Age 18-45\n3. Subjects are active aerobic athletes, training regularly more than 4 exercise sessions per week.\n4. Subject willing and able to read, understand and sign an informed consent\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits and\u002For comply with the study protocol\n2. Active malignancy\n3. Active smokers\n4. Previous treatment of HBOT for any reason prior to study enrollment.\n5. Chest pathology incompatible with pressure changes\n6. Major orthopedic injury at the past 3 months\n7. Inner ear disease\n8. Lung pathology\n9. The inability to perform an awake brain MRI\n10. Claustrophobia\n11. Previous neurologic conditions (e.g., Epilepsy, Brain tumors or s\u002Fp neurosurgery etc.)\n12. Comorbidities and medications that rule out the subject",{"count":287,"type":21},66,[24],"Comparing the effect of HBOT and IHT on aerobic performance of athletes.",[291],"Healthy Active Athletes",[293,294,295,71,296,297],"triathletes","cyclists","mitochondria","HBO","IHT",{"date":230,"type":32},{"date":300,"type":32},"2023-06-01",{"date":149,"type":21},{"name":38,"class":39},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":320,"leadSponsor":321,"locationsCount":64},"100412215","hyperbaric-oxygen-therapy-for-post-covid-19-syndrome-100412215","NCT04647656","Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome","Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome: a Prospective, Randomized, Double Blind Study.","HBOTpCOVID","Inclusion Criteria:\n\n1. Age above 18 years\n2. Reported post COVID-19 cognitive deterioration that effect quality of life and persist at least 3 months after confirmed infection.\n3. Subject willing and able to read, understand and sign an informed consent\n\nExclusion Criteria:\n\n1. Inability to attend scheduled clinic visits and\u002For comply with the study protocol\n2. History of traumatic brain injury (TBI) or any other non COVID brain pathology\n3. Active malignancy\n4. Substance use at baseline\n5. Severe or unstable physical disorders or major cognitive deficits at baseline\n6. HBOT for any reason prior to study enrolment\n7. Chest pathology incompatible with pressure changes (including moderate to severe asthma)\n8. Ear or Sinus pathology incompatible with pressure changes\n9. An inability to perform an awake brain MRI\n10. Active smoking",{"count":312,"type":21},91,[24],"Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome",[316,317],"Covid19","Neurocognitive Dysfunction",{"date":230,"type":32},{"date":300,"type":32},{"date":149,"type":21},{"name":38,"class":39},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":329,"minAge":18,"maxAge":242,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":337,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":352},"100603981","comparison-of-surgical-management-of-early-pregnancy-loss-by-suction-curettage-versus-hysteroscopy-in-patients-undergoing-in-vitro-fertilization-ivf-100603981","NCT07143578","Comparison of Surgical Management of Early Pregnancy Loss by Suction Curettage Versus Hysteroscopy in Patients Undergoing In-vitro Fertilization (IVF)","Comparison Of Surgical Management Of Early Pregnancy Loss By Suction Curettage Versus Hysteroscopy In Patients Undergoing In-Vitro Fertilization (IVF)","Inclusion Criteria:\n\n1. Diagnosis of early pregnancy loss up to 10 weeks' gestation, based on last menstrual period or ultrasound.\n2. Pregnancy conceived through assisted reproductive techniques (in vitro fertilization, IVF).\n3. Ability to provide informed consent, and proficiency in reading and writing Hebrew.\n\nExclusion Criteria:\n\n1. Heavy vaginal bleeding or diagnosis of incomplete abortion.\n2. Signs of infection and\u002For suspicion of septic abortion\n3. Known uterine anomalies- including septate, bicornuate, unicornuate, or didelphys uterus.\n4. Prior medical or surgical treatment during the current pregnancy\n5. History of intrauterine adhesions\n6. History of ≥ 3 prior miscarriages.\n7. History of ≥ 3 prior cesarean sections.\n8. History of myomectomy via abdominal or hysteroscopic approach.","FEMALE",{"count":331,"type":21},50,[24],"Early pregnancy loss occurs in \\~15% of pregnancies. The treatment options include surgical uterine evacuation by suction curettage, medical management with misoprostol, or conservative management without interventions. The advantages of surgical management include quick resolution of the pregnancy and avoidance of heavy vaginal bleeding, while the disadvantages include retained products of conception and intrauterine adhesion formation which could affect future fertility. With the aim of reducing the complications of suction curettage, uterine evacuation using operative hysteroscopy has been suggested.\n\nIn a previous study, the investigators compared suction curettage with operative hysteroscopy for the surgical management of early pregnancy loss up to 10 weeks of gestation. The results showed significantly reduced adhesions rate (4.2% in the hysteroscopy group vs. 45.2% in the suction group, p \\\u003C 0.01), although the operative time was significantly longer for the hysteroscopy.\n\nIn this follow-up study, the investigators will compare the outcomes of hysteroscopy and suction curettage in a select group of patients with early pregnancy loss following conception by in-vitro fertilization. These patients are at risk for adhesions and therefore candidates for the hysteroscopic intervention. The study will include 50 patients randomized to 2 intervention arms - hysteroscopy using a tissue removal device versus the standard suction curettage. Post-operative adhesions will be assessed by office hysteroscopy after 6-8 weeks.",[335,336],"Early Abortion","Pregnancy Loss, Early",[338,339,340,341,342,343],"hysteroscopy","pregnancy loss","early missed abortion","spontaneous abortion","suction curettage","intrauterine adhesions","2026-01-25",{"date":346,"type":32},"2026-01-27",{"date":348,"type":32},"2025-08-20",{"date":350,"type":21},"2027-08-30",{"name":38,"class":39},2,{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":361,"conditions":362,"keywords":364,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":376,"locationsCount":352},"100618670","metabolic-changes-associated-with-weight-gain-after-treatment-of-achalasia-100618670","NCT07334639","Metabolic Changes Associated With Weight Gain After Treatment of Achalasia","Inclusion Criteria:\n\n* Proven achalasia\n* Undergoing LHM or POEM for treatment\n\nExclusion Criteria:\n\n* Under age 18\n* Does no consent",{"count":360,"type":21},30,"This goal of the study is to assess the effect of weight gain in patients with achalasia after they are treated. The main question to be answered is if weight gain after achalasia treatment is associated with worsening metabolic status. Patients will be compared between their baseline status at the time of treatment and 1 year after treatment. Participants will have metabolic tests performed at these 2 times including blood tests.",[363],"Achalasia, Esophageal",[365,366,367,368,369],"achalasia","weight gain","obesity","metabolic syndrome","hepatic steatosis","2026-01-11",{"date":372,"type":32},"2026-01-13",{"date":374,"type":21},"2026-01-15",{"date":36,"type":21},{"name":38,"class":39},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":385,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":64},"100465814","phase-4-tranexamic-acid-during-colonic-endoscopic-resection-procedures-100465814","NCT05345613","Tranexamic Acid During Colonic Endoscopic Resection Procedures","Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding","Inclusion Criteria:\n\n* Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center.\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* patients with histories of allergic reactions to TXA\n* history of seizures\n* pregnancy",{"count":108,"type":21},[386],"PHASE4","Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.",[389],"Colon Neoplasm","2026-01-10",{"date":372,"type":32},{"date":393,"type":32},"2022-05-01",{"date":395,"type":21},"2026-10-01",{"name":38,"class":39},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":73,"sex":329,"minAge":18,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":64},"100467771","mycotoxins-in-mothers-milk-in-israel-100467771","NCT05371106","Mycotoxins in Mothers Milk in Israel","Maternal and Newborn Exposure to Mycotoxins in Israel and the Association to Baby's Development in First Months of Life","Inclusion Criteria:\n\n* Women aged 18 and above.\n* Pregnant women after week 37 intending to breastfeed.\n* Women breastfeeding.\n\nExclusion Criteria:\n\n* Women taking drugs which influence milk production.\n* Women taking drugs contraindicated during breastfeeding.\n* Women not staying in Israel during third trimester or in the months after birth for a long period of time.\n* Women not wanting\u002Fable to fill up the questionnaires.","55 Years",{"count":406,"type":21},150,"Some plant pathogen fungi may develop in grains, nuts and dry foodstuff during their storage. They secrete toxins which are very resistant and persistent.\n\nThe toxins enter the human body through the food. Women eating without their knowledge spoiled food absorb the toxin which is conveyed into their milk. In the same way, meat and dairy products can be contaminated with mycotoxins.\n\nToxins and their metabolites can have negative effects on pregnant women and on the fetus or infant health.\n\nThe main purpose of this trial is to assess the presence of toxins in mothers's milk.",[409],"Breastfeeding",[411],"mycotoxins","2025-12-18",{"date":414,"type":32},"2025-12-24",{"date":416,"type":32},"2020-09-01",{"date":418,"type":21},"2028-12-31",{"name":38,"class":39},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":64},"100610770","phase-2-sodium-bicarbonate-in-intra-dialytic-hypertension-in-chronic-hemodialysis-patients-100610770","NCT07231900","Sodium Bicarbonate in Intra-dialytic Hypertension in Chronic Hemodialysis Patients","Inclusion Criteria:\n\n* Chronic hemodialysis patient \\> 3 months\n* 3 dialysis per week, KTV\\>1.2\n* capable of informed concent.\n* rise in blood pressure during hemodialysis \\> 10 mm Hg, for at least 50% of dialysis sessions in the month prior to inclusion.\n* Normal volume status, by clinical physician assessment + bioimpedance\n\nExclusion Criteria:\n\n* age under 18,\n* pregnancy\n* unable to sign informed concent\n* planned for kidney transplant in the following 3 month.\n* congestive heart failure (NYHA 3-4)\n* hospitalization for acute MI or CHF in the past 3 months.\n* low compliece to medical therapy\n* regular pre-dialysis tests with bicarbonate \\> 24 in the past 3 months",{"count":182,"type":21},[428,429],"PHASE2","PHASE3","The study is designed to diminish intra-dialytic hypertension in chrnic hemodialysis patients suffering from metabolic acidosis (low bicarbonate levels). The intervention is a tab of 500 mg sodium bicarbonate twice a day for one month, vs. placebo.",[432],"Hypertension in Dialysis Patients",[434],"Intra-dialytic hypertension","2025-11-14",{"date":437,"type":32},"2025-11-17",{"date":439,"type":21},"2025-11-10",{"date":441,"type":21},"2027-12-01",{"name":38,"class":39},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":73,"sex":329,"minAge":18,"maxAge":131,"enrollmentInfo":450,"targetDuration":4,"studyType":22,"phases":452,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":4},"100599244","effect-of-the-bioheat-patch-on-pain-following-the-hyfosy-procedure-100599244","NCT07081971","Effect of the Bioheat Patch on Pain Following the HyFoSy Procedure","B-HyP","Inclusion Criteria:\n\nWomen aged 18-45 scheduled for HyFoSy\n\nNo dermatologic conditions at the patch site\n\nNo allergies to patch ingredients, or heat\n\nNo active pelvic infections\n\nExclusion Criteria:\n\nActive genital infection\n\nSkin issues in lower abdomen\n\nSensitivity to heat\n\nAny medical condition preventing local heat use",{"count":451,"type":21},80,[24],"This randomized controlled trial (RCT) evaluates the efficacy of Bioheat thermal patches in reducing post-procedural pain following Hysterosalpingo Foam Sonography (HyFoSy).\n\nHyFoSy is a common ultrasound-based diagnostic procedure to assess tubal patency and uterine cavity structure in women undergoing fertility workup. While generally less painful than HSG, many patients still report moderate to severe cramping and discomfort during and after the test.\n\nThermal therapy has demonstrated effectiveness in reducing musculoskeletal and gynecological pain. Bioheat patches, approved by the Israeli Ministry of Health for menstrual pain relief, emit safe, low-grade heat (approximately 37-38°C) and may provide a non-invasive pain management strategy post-HyFoSy.\n\nParticipants (n=80) will be women aged 20-45 undergoing HyFoSy. They will be randomly assigned to either the Bioheat intervention group or a placebo patch group, applied externally to the lower abdomen. The heat-producing patch contains iron and other safe materials that react with oxygen to emit continuous heat without electricity. Infrared radiation from the patch components may also promote local vasodilation and muscle relaxation.\n\nPain assessment will use the validated Visual Analog Scale (VAS), collected post-procedure via follow-up SMS and phone contact. The study aims to quantify reduction in perceived pain, and potentially improve patient satisfaction with HyFoSy. Safety has been pre-established, with no reported adverse skin effects when used as instructed.\n\nStudy duration is six months, following ethics approval at the OB-GYN ultrasound department of Shamir Medical Center.",[455,456,457,458],"Pelvic Pain","Infertility","Pain Management","Gynecologic Procedures","2025-07-28",{"date":461,"type":32},"2025-07-30",{"date":463,"type":21},"2025-08-01",{"date":465,"type":21},"2025-12-30",{"name":38,"class":39},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":22,"phases":476,"briefSummary":477,"conditions":478,"keywords":482,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":64},"100571792","sensory-rehabilitation-in-chemo-induced-peripheral-neuropathy-100571792","NCT06724861","Sensory Rehabilitation in Chemo Induced Peripheral Neuropathy","Sensory Rehabilitation in CIPN","Inclusion Criteria:\n\n* CIPN by self-report (present or absent) \\> 3 months after last chemotherapy treatment\n* age \\> 18.\n\nExclusion Criteria:\n\n* Pre-chemotherapy neuropathy\u002F sensory impairment\n* recurrent falls prior to chemotherapy (more than 2 per year)\n* CNS involvement\n* not ambulatory before chemotherapy\n* Hebrew proficiency not meeting questionnaires' needs.",{"count":475,"type":21},27,[24],"This study is a cross-over RCT evaluating the effectiveness of 3 sessions a week apart of explicit sensory retraining to the lower extremities in individuals with CIPN versus usual care. The primary outcome measures are TNAS for subjective symptoms, VAS for pain and TUG for mobility. Additional outcome measures are FABS for balance, sensory assessments - monofilaments for touch threshold, LEPT for proprioception, a home exercise log and a satisfaction questionnaire.",[479,480,481],"CIPN - Chemotherapy-Induced Peripheral Neuropathy","Age Over 18","Chemotherapy-induced Peripheral Neuropathy",[483,484,485,486,487],"Neuropathic pain","Chemo Induced Peripheral Neuropathy (CIPN)","Sensory rehabilitation","Explicit Sensory Retraining","Lower extremity","2024-12-05",{"date":490,"type":32},"2024-12-09",{"date":492,"type":21},"2024-12-11",{"date":494,"type":21},"2026-12-11",{"name":38,"class":39},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":503,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":22,"phases":505,"briefSummary":506,"conditions":507,"keywords":510,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":64},"100521312","phase-3-intranasal-dexmedetomidine-for-pain-management-during-screening-for-retinopathy-of-prematurity-100521312","NCT06067958","Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity","Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity: a Crossover Randomized Controlled Trial","Inclusion Criteria:\n\n* Gestational age \\\u003C 31 weeks post-menstrual age, or birth weight \\\u003C 1500 grams\n* Informed consent signed by one of the parents\n\nExclusion Criteria:\n\n* Invasive ventilation at the time of the eye assessment\n* Multiple congenital anomalies\n* Chromosomal \u002F genetic anomalies\n* Infant received a sedative drug in last 5 days\n* Eye examination for reasons other than retinopathy of prematurity screening\n* Attending physician deemed the patient not stable enough","4 Weeks",{"count":360,"type":21},[429],"Background: Preterm infants undergo serial eye examinations during their hospital stay to monitor for the development of a specific disease termed \"retinopathy of prematurity\". While those examinations are known to cause significant pain and stress, the current standard of care (sucrose and local anesthesia) is not adequate in terms of alleviation of pain.\n\nPurpose: The goal of this clinical trial is to test the effectiveness of dexmedetomidine for pain management in preterm infants undergoing routine eye examinations.\n\nThe main questions it aims to answer are:\n\n* Does dexmedetomidine reduce the pain scores of preterm infants during and shortly after eye assessments in comparison to placebo (saline 0.9%).\n* Does dexmedetomidine cause more adverse effects than placebo.\n\nIn this crossover study participants will receive either dexmedetomidine or saline 0.9% intranasally 30 minutes before the examination, on top of the current standard of care. The participants will be monitored closely for 5 hours to note differences in adverse effects. The researchers will use video monitoring to assess the pain scores using a standardized and validated scoring system.",[508,509],"Retinopathy of Prematurity","Dexmedetomidine",[508,509,511,512,513],"Pain","Analgesia","Premature Infant Pain Profile - Revised","2024-12-04",{"date":516,"type":32},"2024-12-06",{"date":518,"type":32},"2023-12-11",{"date":520,"type":21},"2025-12",{"name":38,"class":39},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":529,"maxAge":530,"enrollmentInfo":531,"targetDuration":4,"studyType":22,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":64},"100550783","effect-of-regional-anesthesia-or-intravenous-infusion-of-lidocaine-on-morphine-use-after-scoliosis-repair-surgery-100550783","NCT06451562","Effect of Regional Anesthesia or Intravenous Infusion of Lidocaine on Morphine Use After Scoliosis Repair Surgery","A Controlled Study to Compare the Effect of Regional Anesthesia by an Erector Spine Plane Block and Intravenous Infusion of Lidocaine on the Rate of Intravenous Morphine Use After Scoliosis Repair Surgery","Inclusion Criteria:\n\nPatients over the age of 12 with normal cognition, who are scheduled to undergo surgery to correct scoliosis and treatment with IV PCA independently for pain relief after surgery; The patients' parents\u002Fguardian (in the case of a minor) or the patient himself (in the case of an adult) signed an informed consent form for participation in the study; Patients should be able to operate the PCA device independently\n\nExclusion Criteria:\n\nPatients who do not agree to participate in the study even if their parents signed an informed consent\n\nPatients who are unable to operate the PCA device independently\n\nPatients under treatment with opioids or cannabis for chronic pain for more than a month;\n\nDrug use of any kind;\n\nAlcoholism;\n\nPatients with depression, anxiety or post-trauma;\n\nModerate-severe insufficiency of one of the systems - respiratory\u002Fcardiac\u002Fhepatic\u002Frenal;\n\nSensitivity to one of the drugs in the research protocol.","12 Years","25 Years",{"count":532,"type":21},105,[24],"The goal of the surgical correction of scoliosis is to prevent progression of the curve or progression of restrictive lung disease. After scoliosis surgery, patients experience severe pain. The standard treatment for pain relief after scoliosis surgery is the administration of opiates. However, treatment with these substances involves side effects such as respiratory depression, nausea and vomiting, inhibition of bowel activity and itching. To lower the dose of opiates, different types of painkillers and other techniques can be added.\n\nThe purpose of the study is to compare the effect of instillation of lidocaine (which is an analgesic and anti-inflammatory) or regional anesthesia using Erector spinae plane on the dose of morphine consumption, the intensity of pain, the side effects and the quality of recovery during the first 48 hours after surgery to repair scoliosis.",[536],"Scoliosis","2024-11-10",{"date":539,"type":32},"2024-11-12",{"date":541,"type":32},"2024-09-01",{"date":543,"type":21},"2026-09-30",{"name":38,"class":39},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":329,"minAge":18,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":22,"phases":553,"briefSummary":554,"conditions":555,"keywords":558,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":64},"100566141","preoperative-animated-videos-in-patients-undergoing-operative-hysteroscopy-under-anesthesia-100566141","NCT06651320","Preoperative Animated Videos in Patients Undergoing Operative Hysteroscopy Under Anesthesia","Effect of Preoperative Patient Education Via Animated Videos in Patients Undergoing Operative Hysteroscopy Under Anesthesia","Inclusion Criteria:\n\n* Adult patients (above 18 and older),\n* Patients undergoing operative hysteroscopy under anesthesia in our OR due to uterine findings previously diagnosed during diagnostic hysteroscopy.\n\nExclusion Criteria:\n\n* Patients who are not able to watch the audiovisual video\n* Patients who cannot sign a consent form.",{"count":222,"type":21},[24],"The goal of this clinical trial is to assess if the use of an audiovisual animated video, describing the gynecological procedure (hysteroscopy) the patient is about to undergo, will help to reduce the patient's level of anxiety, affect her anesthesia parameters and increase their overall satisfaction from the procedure.\n\nOur hypothesis is that patient who will watch the video (intervention group) will experience less anxiety, will have lower heart rate and lower blood pressure during the procedure, and have overall more satisfaction with the procedure, compared to patients who will not watch the preoperative video (control group).\n\nPatients will be asked to rate their anxiety level before the procedure and their satisfaction afterwards.",[556,557],"Anxiety","Satisfaction with Care",[338],"2024-10-18",{"date":561,"type":32},"2024-10-21",{"date":563,"type":21},"2024-11-01",{"date":565,"type":21},"2026-02-28",{"name":38,"class":39},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":73,"sex":329,"minAge":18,"maxAge":242,"enrollmentInfo":574,"targetDuration":4,"studyType":22,"phases":575,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":4},"100558733","chromotubation-on-the-remaining-fallopian-tube-after-a-laparoscopic-salpingectomy-due-to-tubal-pregnancy-100558733","NCT06554964","Chromotubation on the Remaining Fallopian Tube After a Laparoscopic Salpingectomy Due to Tubal Pregnancy","Feasibility, Safety and Effectiveness of Chromotubation on the Remaining Fallopian Tube After a Laparoscopic Salpingectomy Due to Tubal Pregnancy","Inclusion Criteria:\n\nPatients undergoing laparoscopic salpingectomy for tubal ectopic pregnancy.\n\nExclusion Criteria:\n\n1. Patients with a history of unilateral salpingectomy\n2. Patients with suspected heterotopic pregnancy\n3. Patients with suspected allergic reaction to blue dye injection",{"count":222,"type":21},[24],"Ectopic pregnancy prevalence is approximately 1-2% of all pregnancies, majority of which located in the fallopian tube. Among the risk factors for ectopic pregnancy is tubal factor - meaning a mechanical problem within the fallopian tube resulting in the pregnancy remaining in the fallopian tube. The treatment o tubal pregnancy can be expectant, medical via metotrexate or surgicl via laparoscopic salpingectomy of the involved fallopian tube. The purpose of this study is to assess the feasibility of chromotubation during laparoscopic salpingectomy for the surgical management of tubal ectopic pregnancy hence assessing the function of the remaining fallopian tube and trying to predict future fertility for the patient.",[578],"Ectopic Pregnancy","2024-10-03",{"date":581,"type":32},"2024-10-08",{"date":583,"type":21},"2024-09-30",{"date":585,"type":21},"2025-09-01",{"name":38,"class":39},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":329,"minAge":18,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":595,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":606,"leadSponsor":608,"locationsCount":4},"100563808","impact-of-different-saline-pressures-during-hysteroscopy-on-visibility-feasibility-and-patients-discomfort-100563808","NCT06620978","Impact of Different Saline Pressures During Hysteroscopy on Visibility, Feasibility and Patients' Discomfort","Operative Hysteroscopy Without Anaesthesia: Impact of Different Distention Medium Pressure (Using Normal Saline) on Visibility, Feasibility and Patients' Discomfort","Inclusion Criteria:\n\n1. Women age \\>18 years\n2. Willing to undergo operative hysteroscopy without anesthesia for\n\nThe following intrauterine findings:\n\nA. Endometrial polyps \\<1.5 cm B. Retained products of conception \\<1.5 cm C. Lysis of intrauterine adhesions D. Removal of retained intrauterine device\n\nExclusion Criteria:\n\n1. Contraindication for hysteroscopy including: suspected pregnancy, heavy concomitant vaginal bleeding, known genital tract malignancy, suspected concurrent genital tract infection.\n2. Unable to sign informed consent\n3. Unable to read\u002Fwrite Hebrew",{"count":222,"type":21},[24],"Hysteroscopy is a minimally invasive diagnostic and therapeutic procedure for various intrauterine conditions. It is performed with an optic device while entering liquid media to the uterus to allow visualization. Diagnostic procedures are often performed without anaesthesia (in the office setting) and operative procedures are performed either under general anaesthesia or without anaesthesia (in the office setting). It depends on the patients' characteristics and preferences, and surgical indications. 80%-100% of operative procedure without anesthesia can be successfully completed. The main reasons for inability to successfully complete operative hysteroscopy without anesthesia are patients' discomfort and limited visibility of the uterine cavity.\n\nIn the current study, the investigators will compare the use of two different pressure setting of the liquid media during operative hysteroscopy without anesthesia, with the aim of investigating the successful completion of the procedure and patient's discomfort, with the aim of determining the optimal pressure setting.",[598,599,600,601],"Endometrial Polyps","Retained Products of Conception","Lysis of Intrauterine Adhesions","Removal of Retained Intrauterine Device","2024-10-01",{"date":604,"type":32},"2024-10-02",{"date":563,"type":21},{"date":607,"type":21},"2025-12-31",{"name":38,"class":39},""]